<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">442826</article-id><article-id pub-id-type="doi">10.17816/dv442826</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The effectiveness of microneedling and cosmetic camouflage in the treatment of vitiligo</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность применения микронидлинга и медицинского камуфляжа в комплексной терапии витилиго</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4767-3002</contrib-id><contrib-id contrib-id-type="spin">2091-1301</contrib-id><name-alternatives><name xml:lang="en"><surname>Lecaillon</surname><given-names>Makhabbat G.</given-names></name><name xml:lang="ru"><surname>Лекайон</surname><given-names>Махаббат Галимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>askmaha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4580-6193</contrib-id><contrib-id contrib-id-type="spin">4784-9730</contrib-id><name-alternatives><name xml:lang="en"><surname>Lomonosov</surname><given-names>Konstantin M.</given-names></name><name xml:lang="ru"><surname>Ломоносов</surname><given-names>Константин Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>lamclinic@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7343-7252</contrib-id><contrib-id contrib-id-type="spin">6091-6469</contrib-id><name-alternatives><name xml:lang="en"><surname>Krotkova</surname><given-names>Elizaveta A.</given-names></name><name xml:lang="ru"><surname>Кроткова</surname><given-names>Елизавета Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>elise1197@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-09-08" publication-format="electronic"><day>08</day><month>09</month><year>2023</year></pub-date><volume>26</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>383</fpage><lpage>391</lpage><history><date date-type="received" iso-8601-date="2023-05-23"><day>23</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-27"><day>27</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Lecaillon M.G., Lomonosov K.M., Krotkova E.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Лекайон М.Г., Ломоносов К.М., Кроткова Е.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Lecaillon M.G., Lomonosov K.M., Krotkova E.A.</copyright-holder><copyright-holder xml:lang="ru">Лекайон М.Г., Ломоносов К.М., Кроткова Е.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-09-08"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/442826">https://rjsvd.com/1560-9588/article/view/442826</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND:</italic></bold> Treatment of vitiligo is one of the most difficult problems in dermatology. Despite the availability of various safe and effective methods of treatment, there are problems with combining and correctly applying techniques for the most effective result. Vitiligo has an impact on the psycho-social aspects of patients' daily life. This makes it necessary to use additional techniques, such as cosmetic camouflage to improve the quality of life of patients with vitiligo.</p> <p><bold><italic>AIM:</italic></bold> to assess the effectiveness of microneedling and cosmetic camouflage for the treatment of vitiligo.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold> The study included 78 people with vitiligo aged 28–46 years. At the first stage of the study, 49 patients underwent microneedling in combination with ultraviolet B therapy and local tacrolimus. The subjects of the control group (<italic>n</italic>=29) were affected only by ultraviolet B therapy and tacrolimus. Phototherapy with ultraviolet B rays of 311 nm was carried out according to the method of 3-fold irradiation per week (Monday, Wednesday, Friday) with an initial dose of 0.05 J/cm<sup>2</sup>. 0.1% tacrolimus ointment was applied twice a day during the course of therapy. The treatment lasted for 2–5 months; 2 courses of 2 months were carried out with a break of 3 months (in total 5 months). On average, for therapeutic effect (complete or partial repigmentation), patients received 60–64 sessions. Patients of the studied groups underwent a comparative analysis of repigmentation 2 and 5 months after treatment. At the second stage of the study, patients after microneedling were divided into the main group (<italic>n</italic>=33) and the comparison group (<italic>n</italic>=16). The subjects of the comparison group underwent cosmetic camouflage of vitiligo sites. Before and after treatment, the dermatological index of quality of life was determined for patients.</p> <p><bold><italic>RESULTS:</italic></bold> After 1 month from the start of treatment, 67.4% of patients after microneedling and 6.1% of patients in the control group showed moderate improvement (26–50% repigmentation). There was a good improvement with 51–75% repigmentation in 26.5% of patients after microneedling. After 5 months from the start of treatment, 67.4% of the subjects after microneedling showed an improvement in repigmentation of more than 51%. It was found that the average indicators of the dermatological quality of life index after treatment in patients of the main group (9.6±0.3 points) and the comparison group (7.0±0.3 points) corresponded to the values of "moderate effect of the disease on quality of life" and were significantly (<italic>p</italic>=0.018) lower than the baseline level (20.8±0.2 points and 19.9±1.1 points). This was not determined in the control group (18.2±0.4 points and 22.4±0.1 points). In the comparison group, this indicator was significantly (<italic>p</italic>=0.001) lower in comparison with the scores of other study groups.</p> <p><bold><italic>CONCLUSION:</italic></bold> The combination of microneedling, ultraviolet B therapy and tacrolimus is an effective method of treating patients with vitiligo. It increases repigmentation and quality of life. Additional cosmetic camouflage improves various aspects of the life of patients with vitiligo.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Лечение витилиго является одной из сложных проблем в дерматологии. Несмотря на появление различных безопасных и эффективных методов лечения витилиго, сохраняются вопросы относительно сочетания и схем применения существующих методик для получения наиболее эффективного результата. Кроме того, витилиго оказывает влияние на психосоциальные аспекты повседневной жизни, что обусловливает необходимость применения дополнительных методик, таких как медицинский камуфляж, с целью улучшения качества жизни таких пациентов.</p> <p><bold>Цель исследования</bold> ― оценка эффективности применения микронидлинга и медицинского камуфляжа в комплексном лечении витилиго.</p> <p><bold>Материал и методы.</bold> В исследование включены 78 человек с витилиго в возрасте 28–46 лет. На первом этапе исследования 49 пациентам проведена процедура микронидлинга по схеме в комплексе с фототерапией и местным применением такролимуса. Обследуемые контрольной группы (<italic>n</italic>=29) получали только УФБ-терапию и такролимус. Фототерапия УФБ-лучами 311 нм проводилась по методике трёхкратного облучения в неделю (понедельник, среда, пятница) с начальной дозы 0,05 Дж/см<sup>2</sup>. Мазь такролимуса 0,1% наносилась дважды в день в течение всего курса терапии. Лечение продолжалось в течение 2–5 месяцев, было проведено 2 курса по 2 месяца с перерывом 3 месяца (в общей сложности 5 месяцев). В среднем для получения терапевтического эффекта в виде полной или частичной репигментации в очагах поражения суммарно больные получили по 60–64 сеанса. Пациентам исследуемых групп выполнен сравнительный анализ статуса репигментации через 2 и 5 месяцев после лечения. На втором этапе исследования после процедур микронидлинга пациенты были разделены на две группы ― основную (<italic>n</italic>=33) и сравнения (<italic>n</italic>=16). Участникам группы сравнения выполнено медицинское камуфлирование зон витилиго. До и после лечения пациентам проведено анкетирование с определением дерматологического индекса качества жизни.</p> <p><bold>Результаты.</bold> Через 2 месяца от начала лечения у 67,4% пациентов после микронидлинга и у 6,1% пациентов контрольной группы выявлено умеренное улучшение очагов поражения (репигментация 26–50%). У 26,5% пациентов после микронидлинга отмечено хорошее улучшение с репигментацией 51–75%. Через 5 месяцев от начала лечения у 67,4% обследуемых после микронидлинга выявлено улучшение репигментации более 51%. Установлено, что средние показатели дерматологического индекса качества жизни после лечения у пациентов основной группы (9,6±0,3 балла) и группы сравнения (7,0±0,3 балла) соответствовали значениям умеренного влияния заболевания на качество жизни и были достоверно (<italic>р</italic>=0,018) ниже исходного уровня (20,8±0,2 и 19,9±1,1 балла соответственно). В группе контроля такой тенденции не выявлено (18,2±0,4 и 22,4±0,1 балла). В группе сравнения данный показатель был достоверно (<italic>р</italic>=0,001) ниже, чем в других группах исследования.</p> <p><bold>Заключение</bold>. Сочетание микронидлинга, фототерапии и такролимуса является эффективным методом лечения пациентов с витилиго, повышающим процессы репигментации и качество жизни. Дополнительное проведение медицинского камуфлирования улучшает различные аспекты жизнедеятельности пациентов с витилиго.</p> <p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>vitiligo</kwd><kwd>microneedling</kwd><kwd>camouflage</kwd><kwd>repigmentation</kwd><kwd>quality of life</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>витилиго</kwd><kwd>микронидлинг</kwd><kwd>медицинский камуфляж</kwd><kwd>репигментация</kwd><kwd>качество жизни</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Bergqvist C, Ezzedine K. Vitiligo: A review. Dermatology. 2020;236(6):571–592. doi: 10.1159/000506103</mixed-citation><mixed-citation xml:lang="ru">Bergqvist C., Ezzedine K. Vitiligo: A review // Dermatology. 2020. Vol. 236, N 6. P. 571–592. doi: 10.1159/000506103</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Lomonosov KM, Rem MA, Gorb VA. History of vitiligo experimental study. Russ J Skin Venereal Dis. 2017;20(6):378–380. (In Russ). doi: 10.18821/1560-9588-2017-20-6-378-380</mixed-citation><mixed-citation xml:lang="ru">Ломоносов К.М., Рем М.А., Горб В.А. История экспериментального изучения витилиго // Российский журнал кожных и венерических болезней. 2017. Т. 20, № 6. C. 378–380. doi: 10.18821/1560-9588-2017-20-6-378-380</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Mina M, Elgarhy L, Al-Saeid H, Ibrahim Z. Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo. J Cosmet Dermatol. 2018;17(5):744–751. doi: 10.1111/jocd.12440</mixed-citation><mixed-citation xml:lang="ru">Mina M., Elgarhy L., Al-Saeid H., Ibrahim Z. Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo // J Cosmet Dermatol. 2018. Vol. 17, N 5. P. 744–751. doi: 10.1111/jocd.12440</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Juntongjin P, Toncharoenphong N. Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: a preliminary, randomized double-blinded controlled study. Lasers Med Sci. 2020;35(9):2023–2029. doi: 10.1007/s10103-020-03048-5</mixed-citation><mixed-citation xml:lang="ru">Juntongjin P., Toncharoenphong N. Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: A preliminary, randomized double-blinded controlled study // Lasers Med Sci. 2020. Vol. 35, N 9. P. 2023–2029. doi: 10.1007/s10103-020-03048-5</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">De Baat C, Phoa KH, Zweers PG, et al. Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide. Ned Tijdschr Tandheelkd. 2020;127(4):237–243. doi: 10.5177/ntvt.2020.04.19115</mixed-citation><mixed-citation xml:lang="ru">De Baat C., Phoa K.H., Zweers P.G., et al. Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide // Ned Tijdschr Tandheelkd. 2020. Vol. 127, N 4. P. 237–243. doi: 10.5177/ntvt.2020.04.19115</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Mokhtari F, Bostakian A, Shahmoradi Z, et al. Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol. J Cosmet Dermatol. 2018;17(2):165–170. doi: 10.1111/jocd.12373</mixed-citation><mixed-citation xml:lang="ru">Mokhtari F., Bostakian A., Shahmoradi Z., et al. Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol // J Cosmetic Dermatol. 2018. Vol. 17, N 2. P. 165–170. doi: 10.1111/jocd.12373</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77(1):17–29. doi: 10.1016/j.jaad.2016.11.010</mixed-citation><mixed-citation xml:lang="ru">Rodrigues M., Ezzedine K., Hamzavi I., et al.; Vitiligo Working Group. Current and emerging treatments for vitiligo // J Am Acad Dermatol. 2017. Vol 77, N 1. P. 17–29. doi: 10.1016/j.jaad.2016.11.010</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Gan EY, Eleftheriadou V, Esmat S, et al. Repigmentation in vitiligo: Position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2017;30(1):28–40. doi: 10.1111/pcmr.12561</mixed-citation><mixed-citation xml:lang="ru">Gan E.Y., Eleftheriadou V., Esmat S., et al. Repigmentation in vitiligo: Position paper of the Vitiligo Global Issues Consensus Conference // Pigment Cell Melanoma Res. 2017. Vol. 30, N 1. P. 28–40. doi: 10.1111/pcmr.12561</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Pinson IY, Olisova OY, Bashlakova KA. Clinical efficiency of eximer lamp and laser in vitiligo: A comparative randomized study. Russ J Skin Venereal Dis. 2015;18(5):59–62. (In Russ). doi: 10.17816/dv37025</mixed-citation><mixed-citation xml:lang="ru">Пинсон И.Я., Олисова О.Ю., Башлакова К.А. Сравнение клинической эффективности эксимерных лампы и лазера при витилиго: рандомизированное исследование // Российский журнал кожных и венерических болезней. 2015. Т. 18, № 5. C. 59–62. doi: 10.17816/dv37025</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Iriarte C, Awosika O, Rengifo-Pardo M, Ehrlich A. Review of applications of microneedling in dermatology. Clin Cosmet Investig Dermatol. 2017;(10):289–298. doi: 10.2147/CCID.S142450</mixed-citation><mixed-citation xml:lang="ru">Iriarte C., Awosika O., Rengifo-Pardo M., Ehrlich A. Review of applications of microneedling in dermatology // Clin Cosmet Investig Dermatol. 2017. Vol. 10. P. 289–298. doi: 10.2147/CCID.S142450</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Stanimirovic A, Kovacevic M, Korobko I, et al. Combined therapy for resistant vitiligo lesions: NB-UVB, microneedling, and topical latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB-UVB. Dermatol Ther. 2016;29(5):312–316. doi: 10.1111/dth.12363</mixed-citation><mixed-citation xml:lang="ru">Stanimirovic A., Kovacevic M., Korobko I., et al. Combined therapy for resistant vitiligo lesions: NB-UVB, microneedling, and topical latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB-UVB // Dermatol Ther. 2016. Vol. 29, N 5. P. 312–316. doi: 10.1111/dth.12363</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Giorgio CM, Caccavale S, Fulgione E, et al. Efficacy of microneedling and photodynamic therapy in vitiligo. Dermatol Surg. 2019;45(11):1424–1426. doi: 10.1097/DSS.0000000000001816</mixed-citation><mixed-citation xml:lang="ru">Giorgio C.M., Caccavale S., Fulgione E., et al. Efficacy of microneedling and photodynamic therapy in vitiligo // Dermatol Surg. 2019. Vol. 45, N 11. P. 1424–1426. doi: 10.1097/DSS.0000000000001816</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Wu JH, Cohen BA. The stigma of skin disease. Curr Opin Pediatr. 2019;31(4):509–514. doi: 10.1097/MOP.0000000000000792</mixed-citation><mixed-citation xml:lang="ru">Wu J.H., Cohen B.A. The stigma of skin disease // Curr Opin Pediatr. 2019. Vol. 31, N 4. P. 509–514. doi: 10.1097/MOP.0000000000000792</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Tanioka M, Yamamoto Y, Kato M, Miyachi Y. Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol. 2010;9(1):72–75. doi: 10.1111/j.1473-2165.2010.00479.x</mixed-citation><mixed-citation xml:lang="ru">Tanioka M., Yamamoto Y., Kato M., Miyachi Y. Camouflage for patients with vitiligo vulgaris improved their quality of life // J Cosmet Dermatol. 2010. Vol. 9, N 1. P. 72–75. doi: 10.1111/j.1473-2165.2010.00479.x</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Salloum A, Bazzi N, Maalouf D, Habre M. Microneedling in vitiligo: A systematic review. Dermatol Ther. 2020;33(6):e14297. doi: 10.1111/dth.14297</mixed-citation><mixed-citation xml:lang="ru">Salloum A., Bazzi N., Maalouf D., Habre M. Microneedling in vitiligo: A systematic review // Dermatol Ther. 2020. Vol. 33, N 6. P. e14297. doi: 10.1111/dth.14297</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: A systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338–e339. doi: 10.1111/bjd.15933</mixed-citation><mixed-citation xml:lang="ru">Morrison B., Burden-Teh E., Batchelor J.M., et al. Quality of life in people with vitiligo: A systematic review and meta-analysis // Br J Dermatol. 2017. Vol. 177, N 6. P. e338–e339. doi: 10.1111/bjd.15933</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35(2):117–128. doi: 10.1016/j.det.2016.11.002</mixed-citation><mixed-citation xml:lang="ru">Elbuluk N., Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients // Dermatol Clin. 2017. Vol. 35. P. 117–128. doi: 10.1016/j.det.2016.11.002</mixed-citation></citation-alternatives></ref></ref-list></back></article>
